Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1602606

registered interest
date	08/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the findings of the report by The Association of the British Pharmaceutical Industry False economy? How NHS medicine procurement threatens the UK’s Life Sciences growth engine, published on 23 February, that the continued current high rebate rates under the voluntary and statutory schemes for branded medicines during the next five years would mean foregoing £50 billion in GDP and £17.9 billion in tax revenues as a result of lost research and development investment; and what are their estimates of the value of the potential lost investment in this sector.
tabling member printed	Lord Warner
uin	HL6287
answer	answer is ministerial correction date of answer 23/03/2023 answer text <p>The Department carefully considers all evidence in the public domain on matters relating to the growth and competitiveness of the United Kingdom’s life science sector, including the recent report by the Association of the British Pharmaceutical Industry. This occurs in combination with broad engagement with individual companies, the National Health Service and with charities and patient representatives and will continue moving forward as part of the delivery of the Government’s Life Science Vision.</p> answering member printed Lord Markham grouped question UIN HL6285 question first answered 23/03/2023 11:34:32 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner

1433433

registered interest
date	21/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how much Evusheld monoclonal antibody treatment they have secured; and when this treatment will be available to the clinically vulnerable in the UK.
tabling member printed	Lord Mendelsohn
uin	HL6287
answer	answer is ministerial correction date of answer 28/02/2022 answer text <p>Evusheld is not currently authorised for use in the United Kingdom. We continue to monitor a range of products, including Evusheld. However, we are unable to provide information on negotiations with companies as this is commercially sensitive.</p><p>On 5 October 2021, the Department invited suppliers to submit an expression of interest on neutralising antibody treatments being developed for treating and preventing COVID-19. This will enable the Department to undertake fair and transparent market engagement with suppliers.</p> answering member printed Lord Kamall question first answered 28/02/2022 17:26:48 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn